Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients
Objectives: Because estrogens stimulate the synthesis and release of leptin in the adipocytes, the effect of antiestrogens on the circulating leptin levels were studied. Methods: Thirty postmenopausal patients with breast cancer were randomized to start either with tamoxifen (20 mg/day, n=15) or tor...
Gespeichert in:
| Veröffentlicht in: | Maturitas 2000-05, Vol.35 (2), p.175-179 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 179 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Maturitas |
| container_volume | 35 |
| creator | Marttunen, Merja B Andersson, Sture Hietanen, Päivi Karonen, Sirkka-Liisa Koistinen, Heikki A Koivisto, Veikko A Tiitinen, Aila Ylikorkala, Olavi |
| description | Objectives: Because estrogens stimulate the synthesis and release of leptin in the adipocytes, the effect of antiestrogens on the circulating leptin levels were studied.
Methods: Thirty postmenopausal patients with breast cancer were randomized to start either with tamoxifen (20 mg/day,
n=15) or toremifene (40 mg/day,
n=15), and the patients were examined and serum leptin concentrations measured before the study and at 6 and 12 months.
Results: The baseline leptin concentrations ranged from 4.4 to 60.0 μg/l (15.3±13.1 μg/l, mean±S.D.), and it correlated positively with the body mass index (BMI) of the subjects (
r=0.73,
P=0.0001). Taking as a whole the antiestrogen regimen was associated with elevated leptin levels at 6 months (19.5±13.8 μg/l,
P=0.0001) but no excess increase in leptin levels were seen at 12 months (20.9±13.5 μg/l, NS). Subgroup analysis showed no difference between the effects of tamoxifen or toremifene on leptin. BMI increased in 21 women (from 26.2±4.3 to 27.3±4.8 kg/m
2,
P=0.0001) at 6 months, but not after that; in nine women BMI did not change. There was no significant correlation between the change in leptin levels and the change in BMI in either group implying that antiestrogens may specifically stimulate leptin production.
Conclusions: Antiestrogens may stimulate the synthesis and release of leptin in the adipocytes. This effect of antiestrogens resembles the effect of estrogen and consequently stimulation of leptin production can be added to the estrogenic effects of antiestrogens. |
| doi_str_mv | 10.1016/S0378-5122(00)00121-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72529369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378512200001213</els_id><sourcerecordid>72529369</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1223e57b6861a2c7c0f0a2607dc0e15fad92067b8ff0ea5e8e511d53f48008d23</originalsourceid><addsrcrecordid>eNqFkEuLFDEQgIMo7uzqT1ByEFkPrVVJpx-nZVl8wYIH9Rwy6YpEupM2SS_6783sDOrNU1HUV6-PsWcIrxGwe_MZZD80CoW4BHgFgAIb-YDtcOhl0yLiQ7b7g5yx85y_A4AC2T5mZwijaIe23bHlOhRPuaT4jYK3vJgl_vSOAjdh4iUmWg4ZcR9sIpOJZ0rbwmdaiw813NGca5GvMZeFQlzNls3M9we4cGuCpcRXU5eEkp-wR87MmZ6e4gX7-u7tl5sPze2n9x9vrm8bK0coTb1Ykur33dChEba34MCIDvrJAqFyZhoFdP1-cA7IKBpIIU5KunYAGCYhL9jL49w1xR9bfU8vPluaZxMobln3QolRdmMF1RG0KeacyOk1-cWkXxpBHzzre8_6IFED6HvPWta-56cF236h6Z-uo9gKvDgBJlszu1RF-PyXa4UaESt2dcSqRbrzlHS21ZSlySeyRU_R_-eS304jm4o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72529369</pqid></control><display><type>article</type><title>Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Marttunen, Merja B ; Andersson, Sture ; Hietanen, Päivi ; Karonen, Sirkka-Liisa ; Koistinen, Heikki A ; Koivisto, Veikko A ; Tiitinen, Aila ; Ylikorkala, Olavi</creator><creatorcontrib>Marttunen, Merja B ; Andersson, Sture ; Hietanen, Päivi ; Karonen, Sirkka-Liisa ; Koistinen, Heikki A ; Koivisto, Veikko A ; Tiitinen, Aila ; Ylikorkala, Olavi</creatorcontrib><description>Objectives: Because estrogens stimulate the synthesis and release of leptin in the adipocytes, the effect of antiestrogens on the circulating leptin levels were studied.
Methods: Thirty postmenopausal patients with breast cancer were randomized to start either with tamoxifen (20 mg/day,
n=15) or toremifene (40 mg/day,
n=15), and the patients were examined and serum leptin concentrations measured before the study and at 6 and 12 months.
Results: The baseline leptin concentrations ranged from 4.4 to 60.0 μg/l (15.3±13.1 μg/l, mean±S.D.), and it correlated positively with the body mass index (BMI) of the subjects (
r=0.73,
P=0.0001). Taking as a whole the antiestrogen regimen was associated with elevated leptin levels at 6 months (19.5±13.8 μg/l,
P=0.0001) but no excess increase in leptin levels were seen at 12 months (20.9±13.5 μg/l, NS). Subgroup analysis showed no difference between the effects of tamoxifen or toremifene on leptin. BMI increased in 21 women (from 26.2±4.3 to 27.3±4.8 kg/m
2,
P=0.0001) at 6 months, but not after that; in nine women BMI did not change. There was no significant correlation between the change in leptin levels and the change in BMI in either group implying that antiestrogens may specifically stimulate leptin production.
Conclusions: Antiestrogens may stimulate the synthesis and release of leptin in the adipocytes. This effect of antiestrogens resembles the effect of estrogen and consequently stimulation of leptin production can be added to the estrogenic effects of antiestrogens.</description><identifier>ISSN: 0378-5122</identifier><identifier>EISSN: 1873-4111</identifier><identifier>DOI: 10.1016/S0378-5122(00)00121-3</identifier><identifier>PMID: 10924844</identifier><identifier>CODEN: MATUDK</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Antineoplastic agents ; Antineoplastic Agents, Hormonal - pharmacology ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - blood ; Breast Neoplasms - prevention & control ; Estrogen Receptor Modulators - pharmacology ; Estrogen Receptor Modulators - therapeutic use ; Female ; General aspects ; Humans ; Leptin ; Leptin - blood ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Postmenopause ; Tamoxifen ; Tamoxifen - pharmacology ; Tamoxifen - therapeutic use ; Toremifene ; Toremifene - pharmacology ; Toremifene - therapeutic use</subject><ispartof>Maturitas, 2000-05, Vol.35 (2), p.175-179</ispartof><rights>2000 Elsevier Science Ireland Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1223e57b6861a2c7c0f0a2607dc0e15fad92067b8ff0ea5e8e511d53f48008d23</citedby><cites>FETCH-LOGICAL-c390t-1223e57b6861a2c7c0f0a2607dc0e15fad92067b8ff0ea5e8e511d53f48008d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0378-5122(00)00121-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1425911$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10924844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marttunen, Merja B</creatorcontrib><creatorcontrib>Andersson, Sture</creatorcontrib><creatorcontrib>Hietanen, Päivi</creatorcontrib><creatorcontrib>Karonen, Sirkka-Liisa</creatorcontrib><creatorcontrib>Koistinen, Heikki A</creatorcontrib><creatorcontrib>Koivisto, Veikko A</creatorcontrib><creatorcontrib>Tiitinen, Aila</creatorcontrib><creatorcontrib>Ylikorkala, Olavi</creatorcontrib><title>Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients</title><title>Maturitas</title><addtitle>Maturitas</addtitle><description>Objectives: Because estrogens stimulate the synthesis and release of leptin in the adipocytes, the effect of antiestrogens on the circulating leptin levels were studied.
Methods: Thirty postmenopausal patients with breast cancer were randomized to start either with tamoxifen (20 mg/day,
n=15) or toremifene (40 mg/day,
n=15), and the patients were examined and serum leptin concentrations measured before the study and at 6 and 12 months.
Results: The baseline leptin concentrations ranged from 4.4 to 60.0 μg/l (15.3±13.1 μg/l, mean±S.D.), and it correlated positively with the body mass index (BMI) of the subjects (
r=0.73,
P=0.0001). Taking as a whole the antiestrogen regimen was associated with elevated leptin levels at 6 months (19.5±13.8 μg/l,
P=0.0001) but no excess increase in leptin levels were seen at 12 months (20.9±13.5 μg/l, NS). Subgroup analysis showed no difference between the effects of tamoxifen or toremifene on leptin. BMI increased in 21 women (from 26.2±4.3 to 27.3±4.8 kg/m
2,
P=0.0001) at 6 months, but not after that; in nine women BMI did not change. There was no significant correlation between the change in leptin levels and the change in BMI in either group implying that antiestrogens may specifically stimulate leptin production.
Conclusions: Antiestrogens may stimulate the synthesis and release of leptin in the adipocytes. This effect of antiestrogens resembles the effect of estrogen and consequently stimulation of leptin production can be added to the estrogenic effects of antiestrogens.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Hormonal - pharmacology</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Estrogen Receptor Modulators - pharmacology</subject><subject>Estrogen Receptor Modulators - therapeutic use</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Leptin</subject><subject>Leptin - blood</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopause</subject><subject>Tamoxifen</subject><subject>Tamoxifen - pharmacology</subject><subject>Tamoxifen - therapeutic use</subject><subject>Toremifene</subject><subject>Toremifene - pharmacology</subject><subject>Toremifene - therapeutic use</subject><issn>0378-5122</issn><issn>1873-4111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuLFDEQgIMo7uzqT1ByEFkPrVVJpx-nZVl8wYIH9Rwy6YpEupM2SS_6783sDOrNU1HUV6-PsWcIrxGwe_MZZD80CoW4BHgFgAIb-YDtcOhl0yLiQ7b7g5yx85y_A4AC2T5mZwijaIe23bHlOhRPuaT4jYK3vJgl_vSOAjdh4iUmWg4ZcR9sIpOJZ0rbwmdaiw813NGca5GvMZeFQlzNls3M9we4cGuCpcRXU5eEkp-wR87MmZ6e4gX7-u7tl5sPze2n9x9vrm8bK0coTb1Ykur33dChEba34MCIDvrJAqFyZhoFdP1-cA7IKBpIIU5KunYAGCYhL9jL49w1xR9bfU8vPluaZxMobln3QolRdmMF1RG0KeacyOk1-cWkXxpBHzzre8_6IFED6HvPWta-56cF236h6Z-uo9gKvDgBJlszu1RF-PyXa4UaESt2dcSqRbrzlHS21ZSlySeyRU_R_-eS304jm4o</recordid><startdate>20000529</startdate><enddate>20000529</enddate><creator>Marttunen, Merja B</creator><creator>Andersson, Sture</creator><creator>Hietanen, Päivi</creator><creator>Karonen, Sirkka-Liisa</creator><creator>Koistinen, Heikki A</creator><creator>Koivisto, Veikko A</creator><creator>Tiitinen, Aila</creator><creator>Ylikorkala, Olavi</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000529</creationdate><title>Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients</title><author>Marttunen, Merja B ; Andersson, Sture ; Hietanen, Päivi ; Karonen, Sirkka-Liisa ; Koistinen, Heikki A ; Koivisto, Veikko A ; Tiitinen, Aila ; Ylikorkala, Olavi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1223e57b6861a2c7c0f0a2607dc0e15fad92067b8ff0ea5e8e511d53f48008d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Hormonal - pharmacology</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Estrogen Receptor Modulators - pharmacology</topic><topic>Estrogen Receptor Modulators - therapeutic use</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Leptin</topic><topic>Leptin - blood</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopause</topic><topic>Tamoxifen</topic><topic>Tamoxifen - pharmacology</topic><topic>Tamoxifen - therapeutic use</topic><topic>Toremifene</topic><topic>Toremifene - pharmacology</topic><topic>Toremifene - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marttunen, Merja B</creatorcontrib><creatorcontrib>Andersson, Sture</creatorcontrib><creatorcontrib>Hietanen, Päivi</creatorcontrib><creatorcontrib>Karonen, Sirkka-Liisa</creatorcontrib><creatorcontrib>Koistinen, Heikki A</creatorcontrib><creatorcontrib>Koivisto, Veikko A</creatorcontrib><creatorcontrib>Tiitinen, Aila</creatorcontrib><creatorcontrib>Ylikorkala, Olavi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Maturitas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marttunen, Merja B</au><au>Andersson, Sture</au><au>Hietanen, Päivi</au><au>Karonen, Sirkka-Liisa</au><au>Koistinen, Heikki A</au><au>Koivisto, Veikko A</au><au>Tiitinen, Aila</au><au>Ylikorkala, Olavi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients</atitle><jtitle>Maturitas</jtitle><addtitle>Maturitas</addtitle><date>2000-05-29</date><risdate>2000</risdate><volume>35</volume><issue>2</issue><spage>175</spage><epage>179</epage><pages>175-179</pages><issn>0378-5122</issn><eissn>1873-4111</eissn><coden>MATUDK</coden><abstract>Objectives: Because estrogens stimulate the synthesis and release of leptin in the adipocytes, the effect of antiestrogens on the circulating leptin levels were studied.
Methods: Thirty postmenopausal patients with breast cancer were randomized to start either with tamoxifen (20 mg/day,
n=15) or toremifene (40 mg/day,
n=15), and the patients were examined and serum leptin concentrations measured before the study and at 6 and 12 months.
Results: The baseline leptin concentrations ranged from 4.4 to 60.0 μg/l (15.3±13.1 μg/l, mean±S.D.), and it correlated positively with the body mass index (BMI) of the subjects (
r=0.73,
P=0.0001). Taking as a whole the antiestrogen regimen was associated with elevated leptin levels at 6 months (19.5±13.8 μg/l,
P=0.0001) but no excess increase in leptin levels were seen at 12 months (20.9±13.5 μg/l, NS). Subgroup analysis showed no difference between the effects of tamoxifen or toremifene on leptin. BMI increased in 21 women (from 26.2±4.3 to 27.3±4.8 kg/m
2,
P=0.0001) at 6 months, but not after that; in nine women BMI did not change. There was no significant correlation between the change in leptin levels and the change in BMI in either group implying that antiestrogens may specifically stimulate leptin production.
Conclusions: Antiestrogens may stimulate the synthesis and release of leptin in the adipocytes. This effect of antiestrogens resembles the effect of estrogen and consequently stimulation of leptin production can be added to the estrogenic effects of antiestrogens.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>10924844</pmid><doi>10.1016/S0378-5122(00)00121-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5122 |
| ispartof | Maturitas, 2000-05, Vol.35 (2), p.175-179 |
| issn | 0378-5122 1873-4111 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72529369 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic agents Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - prevention & control Estrogen Receptor Modulators - pharmacology Estrogen Receptor Modulators - therapeutic use Female General aspects Humans Leptin Leptin - blood Medical sciences Middle Aged Pharmacology. Drug treatments Postmenopause Tamoxifen Tamoxifen - pharmacology Tamoxifen - therapeutic use Toremifene Toremifene - pharmacology Toremifene - therapeutic use |
| title | Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A09%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiestrogenic%20tamoxifen%20and%20toremifene%20increase%20serum%20leptin%20levels%20in%20postmenopausal%20breast%20cancer%20patients&rft.jtitle=Maturitas&rft.au=Marttunen,%20Merja%20B&rft.date=2000-05-29&rft.volume=35&rft.issue=2&rft.spage=175&rft.epage=179&rft.pages=175-179&rft.issn=0378-5122&rft.eissn=1873-4111&rft.coden=MATUDK&rft_id=info:doi/10.1016/S0378-5122(00)00121-3&rft_dat=%3Cproquest_cross%3E72529369%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72529369&rft_id=info:pmid/10924844&rft_els_id=S0378512200001213&rfr_iscdi=true |